Findings indicate that Black women had a lower odds of being diagnosed with ER+/PR+/HER2+ (OR 0.80, 95% CI 0.70–0.91) and ER+/PR+/HER2− (OR 0.69, 95% CI 0.63–0.76) tumours when compared to White women. The gene discussed is ERBB2; the disease is neoplasm.